Charles River Laboratories International (NYSE:CRL) Stock Price Up 8% – Still a Buy?

Charles River Laboratories International, Inc. (NYSE:CRL) shares traded up 8% during trading on Tuesday . The stock traded as high as $241.50 and last traded at $242.2370. 120,726 shares changed hands during trading, a decline of 87% from the average daily volume of 911,609 shares. The stock had previously closed at $224.30.

Analysts Set New Price Targets

CRL has been the topic of a number of research analyst reports. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a report on Friday, May 8th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. Mizuho upped their price objective on Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Morgan Stanley raised their price objective on Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Finally, Evercore reiterated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a research report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $220.75.

Charles River Laboratories International Price Performance

The business has a 50-day moving average of $203.64 and a two-hundred day moving average of $187.73. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The firm has a market cap of $11.35 billion, a P/E ratio of -62.66, a price-to-earnings-growth ratio of 2.68 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same period in the previous year, the business posted $2.34 earnings per share. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds have recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its position in shares of Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after purchasing an additional 1,074 shares in the last quarter. Empowered Funds LLC bought a new position in Charles River Laboratories International during the first quarter worth $418,000. American Century Companies Inc. increased its stake in Charles River Laboratories International by 41.9% in the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after purchasing an additional 1,616 shares in the last quarter. Brown Advisory Inc. boosted its position in shares of Charles River Laboratories International by 5.1% during the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares in the last quarter. Finally, California Public Employees Retirement System increased its position in Charles River Laboratories International by 3.9% in the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock valued at $12,837,000 after buying an additional 3,198 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.